We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on the medicines.ie website. Find out more

GlaxoSmithKline Consumer Healthcare (Ireland) Ltd

Stonemason's Way, Rathfarnham, Dublin 16,
Telephone: +353 1 495 5000
Fax: +353 1 495 5105
Medical Information Direct Line: 1800 441 442
Medical Information Facsimile: +353 1 495 5242


Summary of Product Characteristics last updated on medicines.ie: 27/02/2013
SPC Polytar Liquid 1% w/w Shampoo



Go to top of the page
1. NAME OF THE MEDICINAL PRODUCT

Polytar Liquid 1% w/w Shampoo


Go to top of the page
2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Tar Blend 1.00 % w/w comprises:

Tar 0.3 % w/w
Cade Oil 0.3 % w/w
Coal Tar Solution 0.1 % w/w
Arachis Oil* extract of Coal Tar 0.3 % w/w

* also known as peanut oil

For a full list of excipients, see section 6.1


Go to top of the page
3. PHARMACEUTICAL FORM

Shampoo.

Clear brownish liquid with an odour of tar.


Go to top of the page
4. CLINICAL PARTICULARS

Go to top of the page
4.1 Therapeutic indications

Polytar Liquid is indicated in the treatment of scalp disorders including psoriasis, dandruff, seborrhoea, eczema and pruritus. Polytar Liquid is also of value in the removal of ointments and pastes used in the treatment of psoriasis.


Go to top of the page
4.2 Posology and method of administration

The hair should be wetted and sufficient Polytar Liquid applied to produce an abundant lather. The scalp and adjacent areas should be vigorously massaged with the fingertips. The hair should then be thoroughly rinsed and the procedure repeated.

Polytar Liquid should be used once or twice weekly.


Go to top of the page
4.3 Contraindications

Known hypersensitivity to the ingredients.


Go to top of the page
4.4 Special warnings and precautions for use

Polytar Liquid contains Arachis oil (peanut oil) and should not be applied by patients known to be allergic to peanut. As there is a possible relationship between allergy to peanut and Soya, patients with Soya allergy should also avoid Polytar Liquid.


Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

None.


Go to top of the page
4.6 Pregnancy and lactation

There are no restrictions on the use of Polytar Liquid in pregnancy or lactation.


Go to top of the page
4.7 Effects on ability to drive and use machines

None.


Go to top of the page
4.8 Undesirable effects

Tar products may cause skin irritation, rashes and rarely photosensitivity. If irritation occurs and persists, treatment should be discontinued. Experience of many years of marketing has shown that the incidence of adverse reactions to Polytar Liquid is less than one percent. These reactions of erythema, dryness, contact dermatitis, irritation and acne-like eruptions are mild and of very low incidence.

An increased risk of skin cancer in patients with psoriasis treated with a combination of coal tar and UVB radiation has been reported. There is no unequivocal evidence to link the use of topically applied coal tar products with skin cancer. See also Section 5.3.


Go to top of the page
4.9 Overdose

Not applicable.


Go to top of the page
5. PHARMACOLOGICAL PROPERTIES

Go to top of the page
5.1 Pharmacodynamic properties

Tars suppress DNA synthesis in hyperplastic skin, inhibiting mitotic activity and protein synthesis. They decrease epidermal proliferation and dermal infiltration and thus promote a return to normal keratinisation.

Tars also have vasoconstrictor, antipruritic and antiseptic properties.


Go to top of the page
5.2 Pharmacokinetic properties

Not applicable.


Go to top of the page
5.3 Preclinical safety data

Tar preparations have been in wide use for many years. Although coal tar preparations containing polycyclic hydrocarbons (PAH's) have been demonstrated to be carcinogenic in the skin of experimental animals, present evidence, based upon epidemiology studies in human and follow-up trials, reveals no evidence of increased risk of skin or internal cancer, particularly when the product is a rinse off shampoo used twice weekly.


Go to top of the page
6. PHARMACEUTICAL PARTICULARS

Go to top of the page
6.1 List of excipient(s)

Coconut Diethanolamine

Hexylene Glycol

Oleyl Alcohol

Polysorbate 80

Triethanolamine Lauryl Sulphate (42% Solution)

Sodium Chloride

Citric Acid Monohydrate

Octylphenoxy Polyethoxy Ethanol

Fragrance 5412

Imidurea

Purified Water


Go to top of the page
6.2 Incompatibilities

Not applicable.


Go to top of the page
6.3 Shelf life

3 years.


Go to top of the page
6.4 Special precautions for storage

No special precautions for storage


Go to top of the page
6.5 Nature and contents of container

High density polyethylene bottles of 65ml, 150ml, 250ml and 500ml.

Not all pack sizes may be marketed.


Go to top of the page
6.6 Special precautions for disposal and other handling

No special requirements.


Go to top of the page
7. MARKETING AUTHORISATION HOLDER

GlaxoSmithKline Consumer Healthcare (Ireland) Limited

Stonemasons Way

Rathfarnham

Dublin 16

Ireland


Go to top of the page
8. MARKETING AUTHORISATION NUMBER(S)

PA 0678/116/001


Go to top of the page
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorization: 01 October 1984

Date of last renewal: 01 October 2009


Go to top of the page
10. DATE OF REVISION OF THE TEXT

February 2013



Link to this document from your website:
http://www.medicines.ie/medicine/10098/SPC/Polytar+Liquid+1++w+w+Shampoo/

Document Links

 
  Link to this page
  View all medicines
from this company
Print this page
View document history
Bookmark and Share

Active Ingredients

 
   Tar Blend